Evidence map›Paper›PMID 35671005›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise.

Harry H Yoon, Haidong Dong, Qian Shi

Open access · bronzeAbstract readEditorialComment
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Harry H YoonDepartment of Oncology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0001-6208-3487
Haidong DongDepartment of Immunology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-5782-2983
Qian ShiDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-4640-8832
Mayo Clinic · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancerR01CA248147 · NCI · MAYO CLINIC ROCHESTER · PI Harry H Yoon · 2021 to 2026
$3.9M
Targeting dual functions of PD-L1 for cancer therapyR01CA256927 · NCI · MAYO CLINIC ROCHESTER · PI DONG, HAIDONG · 2021 to 2025
$1.8M
NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA248147NCI NIH HHS R01 CA256927
6 · The paper itself

Abstract

Exploratory analysis of a phase III trial in esophageal cancer found that the patients who most contributed to an overall survival benefit from PD-1 blockade were not responders, but non-responders. The analysis has limitations but may have implications for investigating the optimal timing of immunotherapy relative to other treatments. See related article by Okada et al., p. 3277.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaFollow-Up StudiesHumansImmunotherapyNivolumabProgrammed Cell Death 1 ReceptorNivolumabProgrammed Cell Death 1 Receptor

Identifiers

PMID35671005
PMCPMC9357158
OpenAlexW4282924634

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.